We are Healthy
U.S.

New Head and Neck Cancer Drug Study Has Launched

Patients are now enrolling in a trial for a targeted cancer therapy that aims to improve outcomes for recurrent or metastatic disease.

Updated on Sept. 29, 2026 in Cancer

A glass pharmaceutical vial rests on a sterile white lab surface, reflecting abstract molecular structures in a clean, professional clinical setting.
Corbus Pharmaceuticals has launched its TEMPO-1 clinical trial, evaluating the antibody-drug conjugate CRB-701 for patients with recurrent or metastatic head and neck cancer. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies to prioritize effective new treatments for cancer patients?

Corbus Pharmaceuticals has officially initiated its TEMPO-1 study, a clinical trial evaluating the drug CRB-701 for patients with oropharyngeal squamous cell carcinoma. This new research seeks to address significant unmet needs for individuals facing recurrent or metastatic head and neck cancers.

Why it matters

The study aims to provide the necessary evidence for potential regulatory approval, offering a new potential treatment path for patients with limited options. Given the severity of this cancer, developing more targeted therapies is a critical step in improving long-term survival prospects.

In early-phase analysis of 3.6 mg/kg dosing, researchers observed a 42.9% objective response rate and a median progression-free survival of 5.6 months. The ongoing TEMPO-1 randomized controlled trial will enroll 250 patients to evaluate the drug's performance against standard therapies.

The players

Corbus Pharmaceuticals

A biotechnology company based in Norwood, Massachusetts, focused on developing antibody-drug conjugates for oncology.

The details

CRB-701 is an antibody-drug conjugate designed to target Nectin-4, a protein often expressed on tumor cells. The drug uses a site-specific, cleavable linker and carries a drug-antibody ratio of two, which allows it to deliver chemotherapy directly to cancerous cells while sparing healthy tissue. The trial compares this approach against common investigator-selected treatments, including capecitabine, cetuximab, or docetaxel.

Timeline

  1. September 29, 2026: The first patient was dosed in the TEMPO-1 study.

  2. 2026: The company plans to present Phase 1/2 data at the ASCO Annual Meeting.

Health Landscape

This development reflects an ongoing industry pivot toward highly specific antibody-drug conjugates to treat difficult-to-manage squamous cell carcinomas. It aligns with the FDA's prioritization of expedited pathways for therapies targeting cancers with high mortality rates and limited treatment options.

If you or a loved one are managing recurrent or metastatic head and neck cancer, this trial highlights the emergence of new targeted options that may be worth discussing with an oncologist. Clinical trial participation is an important conversation to have with your care team to determine if experimental therapies align with your specific diagnosis.

The takeaway

The initiation of this study marks a significant step in testing targeted therapies for aggressive head and neck cancers. Patients and their families should consult with their oncologists to stay informed about trial criteria and to monitor for updates on new treatment approvals.

Further reading

For more information on current treatment landscapes, visit Cancer.

Source note: This article includes information reported by The Manila times.

Live Poll

Do you trust pharmaceutical companies to prioritize effective new treatments for cancer patients?